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Angiotensin-IICathepsin G (CatG), a serine protease present inmast cells and neutrophils, can produce angiotensin-II (Ang-II) and
degrade elastin. Here we demonstrate increased CatG expression in smooth muscle cells (SMCs), endothelial cells
(ECs), macrophages, and T cells from human atherosclerotic lesions. In low-density lipoprotein (LDL) receptor-
deﬁcient (Ldlr–/–)mice, the absenceof CatG reduces arterialwall elastin degradation and attenuates early atheroscle-
rosis whenmice consume aWestern diet for 3 months.Whenmice consume this diet for 6 months, however, CatG
deﬁciency exacerbates atherosclerosis in aortic arch without affecting lesion inﬂammatory cell content or extracel-
lularmatrix accumulation, but raises plasma total cholesterol and LDL levels without affecting high-density lipopro-
tein (HDL) or triglyceride levels. Patientswith atherosclerosis also have signiﬁcantly reducedplasmaCatG levels that
correlate inverselywith total cholesterol (r= –0.535, P b 0.0001) and LDL cholesterol (r= –0.559, P b 0.0001), but
not with HDL cholesterol (P= 0.901) or triglycerides (P= 0.186). Such inverse correlations with total choles-
terol (r = –0.504, P b 0.0001) and LDL cholesterol (r = –0.502, P b 0.0001) remain signiﬁcant after adjusting
for lipid lowering treatments among this patient population. Human CatG degrades puriﬁed human LDL, but
not HDL. This study suggests that CatG promotes early atherogenesis through its elastinolytic activity, but sup-
presses late progression of atherosclerosis by degrading LDL without affecting HDL or triglycerides.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Cathepsin G (CatG), a serine protease, localizes inmast cells and neu-
trophils [1–3]. The best known function of CatG in a cardiovascular con-
text is its ability to activate the renin–angiotensin system: CatG produces
angiotensin II (Ang-II) from angiotensin I (Ang-I) and angiotensinogen
[2,4,5]. Considerable data implicate Ang-II in the pathogenesis of athero-
sclerosis [3,6]. Ang-II affects vascular structure and function. In athero-
sclerotic lesions, Ang-II induces smooth muscle cell (SMC) growth and
migration, activates macrophages, increases platelet aggregation, and
causes endothelial dysfunction. It also promotes apoptosis, increases ox-
idative stress, promotes leukocyte adhesion and migration, stimulates
thrombosis, and has proinﬂammatory effects [7,8]. In addition to produc-
ing Ang-II, CatG also activates matrix metalloproteinase (MMP)-1, -2, -3,
and -9 zymogens [9–12] or enhances their expression [13].MMPs partic-
ipate in atherogenesis [14,15]. CatG is also an elastase [16,17] andgham andWomen's Hospital, 77
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is study.collagenase activator [18]. We have recently found that CatG degrades
type I collagen [17], the dominant collagen type in human aortic wall.
Therefore, CatG may contribute to atherogenesis directly via its
elastinolytic and collagenolytic activities or indirectly via its capability
of activating collagenases or MMPs, and producing Ang-II.
While the normal humanaortas containnegligible CatG, its expression
in human atherosclerotic lesions increases by 2-fold as determined by im-
munoblot analysis, and CatG immunolocalizes to leukocytes and mast
cells in the tunica media and adventitia [19]. Increased CatG in aortas
may degrade VE-cadherin andﬁbronectin, thereby enhancing the expres-
sion and activation of MMPs [13] and the interaction of blood-borne leu-
kocytes with the luminal endothelium [20]. A recent study using Apoe–/–
mice demonstrated that CatG insufﬁciency (Apoe–/–Ctsg+/–) signiﬁcantly
reduced lesion collagen and SMC content, and apoptotic cell number
[21], supporting a role of CatG in experimental atherosclerosis.
This study used CatG and low-density lipoprotein receptor (LDLr)
double-deﬁcient mice (Ldlr–/–Ctsg–/–) and examined blood from pa-
tients with atherosclerosis to probe further potential roles of CatG in
atherosclerosis. The ﬁndings implicate CatG in elastin degradation in
early atherogenesis, and in LDL catabolism at a later stage. Patients
with atherosclerosis have a signiﬁcant inverse association between
plasma LDL and CatG.
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2.1. Human atherosclerotic lesion immunohistology and immunoblot
analysis
Human atherosclerotic plaques were obtained at endarterecto-
my (n = 12), and non-atherosclerotic carotid arteries from heart
transplant donors (n = 10), according to protocols pre-approved
by the Human Investigative Review Committee of Brigham and
Women's Hospital. Human atherosclerosis serial cryostat sections
(6 μm) were stained for CatG (1:200, Calbiochem, San Diego, CA),
CD68 (macrophages, 1:700, Dako, Carpinteria, CA). For localization
of CatG to cell types rabbit anti-CatG (1:50) antibody mixed with
mouse anti-CD68 (1:50, Dako), or anti-CD31 (endothelial cells
[ECs], 1:30, Dako), or -α-actin (SMCs, 1:30, Enzo Diagnostics Inc.,
Farmingdale, NY), or -CD4 (T cells, 1:20, BD Biosciences, San Jose,
CA) antibodies. Consequently, sections incubated with mixture of
anti-rabbit Alexa 533 (red, 1:500) and anti-mouse Alexa 488
(green, 1:300, both from Invitrogen, Grand Island, NY). Nuclei
stained with Dapi (NucBlue® Fixed Cell ReadyProbes® Reagent,
Molecular Probes, Eugene, OR) and slides were coverslip with ﬂuo-
rescent mounting medium (Dako). Human carotid atherosclerotic
lesions (n = 7) and non-atherosclerotic carotid arteries (n = 6) were
also lysed in a protein lysis buffer containing 10 mM Tris.HCl, (pH 8.0),
1 mM EDTA, 0.5 mM EGTA, 1% Triton, 0.1% Sodium deoxycholate, 0.1%
SDS, and 140 mM NaCl. Equal protein from each sample was separated
on a 12% SDS-PAGE for immunoblot analysis with rabbit anti-human
CatG polyclonal antibody (1:1000, Calbiochem).Mouse anti-actinmono-
clonal antibody (1:2000, Santa Cruz Biotechnology, Inc., Dallas, TX) was
used to ensure equal protein loading.
2.2. Mouse experimental atherosclerosis
We crossbred Ctsg–/– mice (C57BL/6/129/SvJ) [22] with
atherosclerosis-prone Ldlr–/– mice (C57BL/6, N11, The Jackson Labo-
ratory, Bar Harbor, ME) to generate Ldlr+/–Ctsg+/– breeding pairs to
produce Ldlr–/–Ctsg–/– mice and their littermate Ldlr–/–Ctsg+/+ con-
trol mice. All mice used in this study were male. To induce athero-
sclerosis, 6-week-old mice from each group consumed a Western
diet (C12108, Research Diets Inc.) for 3 months or 6 months. At
each time point, blood pressures were measured and plasma collect-
ed. Lesion characterizations for mouse atherosclerosis, including
thoracic and abdominal aorta oil-red O staining, aortic arch lesion in-
tima and media areas, lesion macrophages (Mac-3, 1:900, BD Biosci-
ences), T cells (CD4, 1:90, BD Biosciences), MHC class II–positive cells
(MHC class-II, 1:250, BD Biosciences), SMCs (α-actin, 1:750, Sigma), col-
lagen (picrosirius red birefringence), elastin (Verhoeff–van Gieson), arch
lipid deposition (0.5% oil-red O), and apoptosis (TUNEL, EMD Millipore,
Billerica, MA) were performed as described previously [23]. The 3-mm
long aortic arch from the brachiocephalic artery to the ascending artery
perpendicular line toward the descending arterywas used for atheroscle-
rotic lesion analysis, as previously described [24]. We captured images
digitally; and measured the stained area using computer-assisted
image quantiﬁcation (Image-Pro Plus software, Media Cybernetics),
and immunopositive cells were counted manually. All mouse exper-
iments were performed, and data were analyzed in a blinded fash-
ion, by at least three observers. All animal procedures conformed
to the Guide for the Care and Use of Laboratory Animals published
by the U.S. National Institutes of Health, and were approved by the
Harvard Medical School Standing Committee on Animals (protocol
# 03759).
2.3. Mouse plasma ELISA
Blood samples were collected from Ldlr–/–Ctsg–/– mice and their lit-
termate Ldlr–/–Ctsg+/+ control mice at harvest by retro-orbital venousplexus puncture. Plasma total cholesterol, triglyceride, and HDL were
determined using ELISA kits according to the manufacturer's instruc-
tions (Pointe Scientiﬁc, Inc., Canton, MI). LDL cholesterol was calculated
as follows: serum LDL cholesterol concentration (mg/dl) = total cho-
lesterol − HDL cholesterol − (triglycerides/5). Mouse plasma Ang-II
and angiotensin-converting enzyme (ACE) levels were determined
using the Ang-II (USCN Life Science Inc., Houston, TX) and ACE (R&D
Systems, Minneapolis, MN) ELISA kits, respectively, according to the
manufacturers' instructions. Both albumin and alanine aminotransfer-
ase (ALT) levels were determined from plasma samples from mice
that consumed a Western diet for 3 or 6 months to assess whether
CatG deﬁciency affected mouse liver functions (Mouse Metabolic Phe-
notyping Center, Yale University School of Medicine, New Haven, CT).
2.4. Blood pressure measurement
Mouse blood pressures were measured at different time points
while consuming a Western diet. To measure blood pressures from
live mice, we used the CODA standard non-invasive blood pressure sys-
tem — the tail–cuff method, according to the manufacturer's instruc-
tions (Kent Scientiﬁc Corporation, Torrington, CT). Brieﬂy, mice were
trained for 3–5 times before the experiments to conﬁrm that they
became accustomed to the tail–cuff procedure. A single investigator re-
corded blood pressures in a quiet environment without disturbance. At
least 30 measurements were obtained from each mouse to determine
themean values of systolic and diastolic blood pressures and heart rate.
2.5. Human patient population and plasma CatG ELISA
A total of 232 patients fromWuhan Union Hospital, Wuhan, China,
were enrolled in the study due to symptoms of chest pain or electrocar-
diogram abnormalities including ST-T abnormalities, and were sched-
uled to undergo coronary angiography. The local Hospital Review
Committee approved the human study protocol, and all patients gave
informed consent. 171 of the 232 subjects were diagnosed with coro-
nary heart disease (CHD)with one ormoremajor coronary arteries hav-
ing≥50% stenosis; 61 subjects had b50% or no luminal narrowing of the
coronary artery, andwere selected as non-CHD controls. Among the 171
patients with CHD, 59 were diagnosed with acute myocardial infarction
(AMI) due to increased levels of creatinine kinase-MB (twofold higher
than the upper reference limit) or troponin-I (ﬁvefold higher than the
upper reference limit), ischemic symptoms, or ST-T abnormalities by
electrocardiography indicative of ischemia and/or infarction; 67 were
diagnosed with unstable angina pectoris (UAP) due to the progression
of ischemic symptoms less than 3 months before admission to the hos-
pital; and 45were diagnosedwith stable angina pectoris (SAP) based on
predictable exertional chest discomfort more than 3 months before en-
rollment. Patients who were treated with anti-inﬂammatory drugs;
whohad connective tissue disease, thromboembolism, disseminated in-
travascular coagulation, advanced liver disease, renal failure, malignant
disease, or other inﬂammatory diseases (such as septicemia or pneumo-
nia); who had other heart diseases such as rheumatic heart disease, val-
vular heart disease, congenital heart disease; who had atrial ﬁbrillation
or had a pacemaker, were excluded. Among all (232) selected patients,
6/61 (9.8%) non-CHD, 22/45 (49%) SAP, 37/67 (55%) UAP, and 37/59
(63%) AMI patients received lipid-lowering treatment with statins.
Human plasma CatG levels were determined using commercial ELISA
kits according to manufacturer's recommendation (Alpco, Salem, NH).
2.6. Isolation and modiﬁcation of LDL and HDL3
Human LDL (d = 1.019–1.050 g/ml) and human HDL3 (d =
1.125–1.210 g/mL) were isolated from plasma of healthy volunteers
(from the Finnish Red Cross Blood Service, Helsinki, Finland) by sequen-
tial ultracentrifugation in the presence of 3 mM EDTA [25,26]. Lipopro-
tein amounts are expressed in terms of their protein concentrations.
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buffered saline with or without 2 mU/ml of human neutrophil CatG
(Calbiochem), after which they underwent FPLC analysis using a
Superose™ 6 column in anÄkta chromatography system (GEHealthcare)
and by monitoring absorbance at 280 nm.Fig. 1. CatG expression in human atherosclerotic lesions. A. Immunostaining of human atherosc
CD68 (macrophage) antibodies on serial frozen sections from representative human atheroscle
(negative control). Inserts with higher magniﬁcations are shown. B. Immunoﬂuorescent doubl
and CD4+ T cells in human atherosclerotic lesions. Insertswith highermagniﬁcations are shown
atherosclerotic lesions (n= 7). β-actin immunoblot was used to ensure equal protein loading. C
as relative ratio to β-actin.2.7. Statistical analysis
Human plasma results are expressed as percentages or median
(minimum, maximum). Differences in frequencies were compared
using the chi-square test. Normal Gaussian distribution of the datalerotic lesion parallel frozen sections with rabbit anti-human CatG andmouse anti-human
rotic lesion and normal human carotid artery. Staining with rabbit IgG showed no staining
e staining localized CatG expression in SMCs (α-actin), ECs (CD31), macrophages (CD68),
on the right. C. Immunoblot analysis of CatG in humannormal carotid arteries (n=6) and
atG immunoblot gel density was quantiﬁedwith ImageJ software and data was presented
2177J. Wang et al. / Biochimica et Biophysica Acta 1842 (2014) 2174–2183was veriﬁed by the Kolmogorov–Smirnov goodness-of-ﬁt test. When-
ever the data were not normally distributed, the Kruskal–Wallis H test
was used, followed by post hoc analysis (Mann–Whitney U test). To an-
alyze the correlation of serum CatG and blood lipids, we used Pearson's
correlation test. To adjust for the impact of statin treatment on the asso-
ciation between plasma CatG and lipid proﬁles, we performed partial
correlation test with the statin treatment as the controlling variable.
All mouse data were expressed as mean ± SEM. Due to our small sam-
ple sizes and often skewed data distributions, we performed a pairwise
non-parametricMann–Whitney test followed by Bonferroni corrections
to examine the statistical signiﬁcances. SPSS 16.0 was used for analysis.3. Results
3.1. CatG expression in human atherosclerotic lesions
Prior studies demonstrated CatG expression inmast cells and neutro-
phils in human atherosclerotic lesions [19,27]. Immunostaining of paral-
lel sections fromhuman carotid atherosclerotic lesionswith a rabbit anti-
human CatG polyclonal antibody demonstrated CatG expression in
macrophage-rich regions, whereas human normal carotid arteries
displayedmuch less immunoreactive CatG (Fig. 1A). Immunoﬂuorescent
double staining demonstrated that not only macrophages, but also α-
actin-positive SMCs, CD31-positive ECs, and CD4+ T cells all contained
CatG protein (Fig. 1B). Therefore, cells other than mast cells and neutro-
phils may contribute to the elevated CatG in human atherosclerotic le-
sions. CatG localizes in intracellular organelles [28], at the cell surface
[29], and also binds to the nucleic acids in the nuclei [30]. Immunoﬂuo-
rescent double staining detected both intracellular and nuclear CatG
(co-localized with DAPI [4′,6′-diamidino-2-phenylindole hydrochloride]
staining) in SMCs, ECs, and macrophages in human atherosclerotic le-
sions (Fig. 1B). CatG expression in human atherosclerotic lesions was
semi-quantiﬁed with immunoblot analysis, followed by densitometric
analysis using ImageJ. Human carotid atherosclerotic lesions contained
signiﬁcantly more CatG protein than did non-atherosclerotic carotid ar-
teries (Fig. 1C).Fig. 2. CatG deﬁciency lowers systolic and diastolic blood pressures (A) and plasma Ang-II
andACE levels (B) in Ldlr–/–Ctsg–/– compared to Ldlr–/–Ctsg+/+mice that consumedaWest-
ern diet for 3 and 6 months as indicated. Data aremean± SE. The number ofmice per ex-
perimental group is indicated in each bar.3.2. CatG deﬁciency reduces blood pressure and plasma Ang-II and ACE
levels in mice with atherosclerosis
The best-known cardiovascular activity of CatG is processing Ang-I
[2]. We have recently shown that inﬂammatory cytokines and high glu-
cose stimulate SMC generation of Ang-II and ACE, processes that can be
fully blocked by a CatG-selective inhibitor or by CatG siRNA [17]. There-
fore, increased CatG in human atherosclerotic lesions suggest a role of
this protease in local production of Ang-II, thereby promoting athero-
genesis and vascular dysfunction. To testwhether expression of CatG af-
fects Ang-II (and ACE) expression and blood pressures, we used
atherosclerosis-prone Ldlr–/– mice and generated CatG and LDLr
double-deﬁcient (Ldlr–/–Ctsg–/–) mice and their littermates (Ldlr–/–
Ctsg+/+). Before consumption of a Western diet, systolic or diastolic
blood pressures did not differ signiﬁcantly between these strains (data
not shown). After having consumed aWestern diet for 3 months, how-
ever, Ldlr–/–Ctsg–/– mice had signiﬁcantly lower systolic and diastolic
blood pressures compared with Ldlr–/–Ctsg+/+ mice (Fig. 2A), but plas-
ma Ang-II and ACE levels did not differ between the groups (Fig. 2B).
After 6 months on this diet, both diastolic blood pressure and plasma
Ang-II and ACE levels remained signiﬁcantly lower in Ldlr–/–Ctsg–/–
mice than in Ldlr–/–Ctsg+/+ mice (Fig. 2A, B). The temporally disperse
changes of Ang-II and ACE concentrations and systolic and diastolic
blood pressures between the two groups of mice from both different
time points suggest a modest role of CatG activity in Ang-II regulation
and blood pressure during atherogenesis. Absence of CatG did not affect
the heart rate (data not shown).3.3. Distinct roles of CatG at different stages of experimental atherosclerosis
Reduced blood pressures and plasma Ang-II and ACE levels in Ldlr–/–
Ctsg–/–mice suggest that thesemice should develop less and smaller ath-
erosclerotic lesions than do the Ldlr–/–Ctsg+/+ mice. En face preparation
andoil-redO stainingquantiﬁed thoracic–abdominal aorta atherosclerot-
ic lesion area or lipid deposition. After consuming a Western diet for
3 months, Ldlr–/–Ctsg–/– mice showed signiﬁcantly smaller oil-red O-
positive areas compared with Ldlr–/–Ctsg+/+ mice. Oil-red O-positive
areas between the two groups of mice did not differ, however, at a later
stage of atherosclerosis, when mice had consumed a Western diet for
6 months (Fig. 3A). Reduced blood pressures in Ldlr–/–Ctsg–/– mice at
the 3-month time point (Fig. 2A) might have contributed to the reduced
atherosclerosis in the thoracic and abdominal aortas. At the 6-month
time point, however, reduced Ang-II and ACE production and blood pres-
sure (Fig. 2A, B) did not explain the unchanged thoracic–abdominal aorta
atherosclerosis.
The aortic arch develops lesions earlier than the thoracic–abdominal
aorta in both Ldlr–/– mice and apolipoprotein E-deﬁcient (Apoe–/–) mice
[31,32]. After 3 months on a Western diet, aortic lesion intima areas
from the 3-mm aortic arch (Fig. 3B) tended to be lower in Ldlr–/–Ctsg–/–
mice, but did not reach statistical signiﬁcance compared with those
from Ldlr–/–Ctsg+/+ mice (P = 0.084). In contrast, Ldlr–/–Ctsg–/– mice
had signiﬁcantly larger aortic arch intima areas than did Ldlr–/–
Ctsg+/+ mice at the later stage of atherosclerosis, when mice had
consumed a Western diet for 6 months (P = 0.003, Fig. 3B). Al-
though not calculated due to technical difﬁculties to maintain all
three breaches (brachiocephalic artery, left common carotid artery,
and left subclavian artery) on the exact same plane during froze tissue
Fig. 3.CatG deﬁciency attenuates early atherogenesis but aggravates later lesions. Atherosclerotic lesion areas in Ldlr–/–Ctsg–/–mice and Ldlr–/–Ctsg+/+mice fed aWestern diet for 3 months
and 6 months. A. Thoracic–abdominal atherosclerotic lesion oil-redO-positive areas. Representative thoracic–abdominal aortas from the 3-month time point are shown on the left. B. Aor-
tic arch intima areas from the perpendicular line between the left edge of the brachiocephalic artery and the ascending aorta to 3mm towards the descending aorta as indicated by dotted
lines (right two panels). Brachiocephalic artery, left common carotid artery, and left subclavian artery are also indicated in the representative aortic arches at the right panels. Data are
mean ± SE. Number of mice per experimental group is indicated in each bar.
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larger in Ldlr–/–Ctsg–/– mice than in Ldlr–/–Ctsg+/+ mice at this late
stage (Fig. 3B, two right panels). Since the plasma Ang-II and ACE levels
and systolic and diastolic blood pressures decreased, rather than in-
creased, in the Ldlr–/–Ctsg–/– mice at this later time point (Fig. 2A, B),
these hemodynamic changes could not themselves explain the in-
creased atherosclerosis from the aortic arch (Fig. 3B). Lesion character-
ization showed no signiﬁcant differences in lesion Mac-3-positive
macrophage content, CD4+ T-cell content, MHC class II-positive area,
α-actin-positive SMC area, collagen content, or arch lipid deposition
area (Fig. 4A–C), suggesting that CatG did not affect atherosclerotic le-
sion inﬂammation or collagen deposition at either the early (3 months)
or the later (6 months) stages. We evaluated the degree of elastin frag-
mentation in longitudinal frozen sections frommouse aortae stained for
elastica by Verhoeff-van Gieson and graded it as follows: grade 1, intact,
well-organized elastic laminae; grade 2, elastic laminae with some in-
terruptions and breaks; and grade 3, severe elastin fragmentation or
loss as described previously [33]. Representative images are presented
in Fig. 4D. Ldlr–/–Ctsg–/– mice had signiﬁcantly lower aortic arch elastin
fragmentation grade than did Ldlr–/–Ctsg+/+ mice at the early stage,
but not at the late stage studied. CatG elastase activity [16,17] may ex-
plain reduced early-stage atherosclerosis in both the thoracic–abdomi-
nal aorta and the aortic arch in Ldlr–/–Ctsg–/–mice (Fig. 3A, B). Increased
atherosclerosis in the aortic arch in Ldlr–/–Ctsg–/–mice (Fig. 3B) suggests
a different mechanism of CatG in atherogenesis, independent of Ang-IIproduction and blood pressure changes. CatG may either promote apo-
ptosis [34,35], or inhibit this process via Ang-II production [36]. Prior
study from CatG-insufﬁcient Apoe–/–Ctsg+/– mice demonstrated re-
duced apoptosis in atherosclerotic lesions [21]. However, TUNEL stain-
ing showed increased apoptosis in atherosclerotic lesions from Ldlr–/–
Ctsg–/–mice at both the 3- and 6-month timepoints (Fig. 4E), suggesting
an indirect role of CatG deﬁciency in apoptosis of cells in atherosclerotic
lesions, a hypothesis that merits further investigation. Consistent with
increased atherosclerosis in the aortic arch of Ldlr–/–Ctsg–/– mice
(Fig. 3B), we detected signiﬁcantly larger necrotic core areas in athero-
sclerotic lesions from Ldlr–/–Ctsg–/– mice than those from Ldlr–/–Ctsg+/+
mice at the later (6 months) time point but not at the early (3 months)
time point, although necrotic core compartments did not differ signiﬁ-
cantly between the two groups at both time points (Fig. 4F). To seek
themechanism(s) bywhich CatG protects against late-stage atheroscle-
rosis in Ldlr–/–Ctsg–/– mice (Figs. 3B, 4F), we measured mouse plasma
lipid proﬁles and found that the absence of CatG increased plasma levels
of total and LDL cholesterol signiﬁcantly at 6 months, but did not affect
these levels at 3 months — nor did it alter plasma triglyceride levels at
either time point or HDL cholesterol levels at the 6-month time point
(Fig. 5A). Plasma total cholesterol and LDL concentration increases in
Ldlr–/–Ctsg–/– mice at a later time point (6 months) suggest that CatG
canmodulate LDLmetabolism. Ldlr–/–Ctsg–/–micehadhigher concentra-
tionsHDL, however, than Ldlr–/–Ctsg+/+mice at the 3-month time point
(Fig. 5A), in association with reduced atherosclerosis in Ldlr–/–Ctsg–/–
Fig. 4.Mouse aortic arch atherosclerotic lesion characterization. Aortic arch lesionMac-3+macrophage areas, CD4+ T-cell numbers, andMHC class-II-positive areas (A), SMC and collagen
contents (B), oil-red O-positive areas (C), elastin fragmentation grades (D), TUNEL-positive cell numbers (E), and lesion necrotic core compartments and areas (F) from Ldlr–/–Ctsg–/–mice
and Ldlr–/–Ctsg+/+ mice fed a Western diet for 3 months and 6 months. Elastin fragmentation grading keys (arrows indicate elastica breaks) are shown to the right of panel D, and rep-
resentative data for TUNEL staining and necrotic cores are shown to right of panels E and F. Data are mean ± SE. Number of mice per experimental group is indicated in each bar.
2179J. Wang et al. / Biochimica et Biophysica Acta 1842 (2014) 2174–2183mice at this early time point (Fig. 3A, B). Increased plasma total or LDL
cholesterol levels from Ldlr–/–Ctsg–/–mice did not result from an altered
liver function, as indicated by the lack of signiﬁcant differences in plas-
ma albumin and alanine aminotransferase levels of Ldlr–/–Ctsg–/– mice
and Ldlr–/–Ctsg+/+ mice either at the 3-month or 6-month time points
(Fig. 5B). These observations suggest that increased atherosclerotic le-
sion sizes at the 6-month time point were resulted at least in part
from increased plasma total and LDL cholesterol levels.
3.4. Correlation between plasma CatG and LDL in patients with
atherosclerosis
The increased LDL and total cholesterol in conjunctionwith accentu-
ated atherosclerosis in Ldlr–/–Ctsg–/– mice well agrees with the well-
known pathogenic role of LDL in Ldlr–/–mice. These ﬁndings suggested
the possibility that CatG also participates in LDLmetabolismby decreas-
ing its concentration in humans, and that CatG could thus protect
humans from atherogenesis. To test this hypothesis, we measured plas-
ma CatG levels and lipid proﬁles in patientswith acutemyocardial infarc-
tion (AMI), unstable angina pectoris (UAP), and stable angina pectoris
(SAP). Patientswith AMI, SAP, andUAP all had signiﬁcantly lower plasma
CatG levels than thosewithout coronary heart diseases (non-CHD group)(Table 1). Pearson's correlation test demonstrated that plasma CatG
levels correlated signiﬁcantly and negativelywith plasma total cholester-
ol (r = –0.535, P= 1.88E−15) and LDL (r = –0.559, P = 4.99E−17),
but not with triglyceride (r = –0.096, P= 0.186) or HDL (r = –0.009,
P= 0.901) (Table 2). Among this population, some received statins to
lower plasma lipid levels, a treatment that might alter their associations
with plasma CatG levels. Therefore, we performed partial correlation
test by adjusting for statin treatment as a controlling variable. The
negative correlations between plasma CatG and plasma total cholester-
ol (r = –0.504, P= 1.37E−13) and LDL (r = –0.502, P= 1.91E−13)
remained signiﬁcant after adjusting for statin use (Table 2). These
human data agreewith the observations from experimental atheroscle-
rosis. Low plasma CatG or genetic deﬁciency of CatG consistently asso-
ciated with plasma total cholesterol and LDL, but not plasma HDL and
triglyceride, in CHD patients (Table 1) or in Ldlr–/–Ctsg–/–mice after con-
suming a Western diet for 6 months (Fig. 5A).
3.5. CatG degrades LDL particles, but not HDL particles
To investigate whether CatG can catabolize plasma lipoproteins, we
puriﬁed human plasma LDL and HDL3 and incubated these lipoproteins
for 18 h with and without 2 mU/mL human neutrophil CatG, after
Fig. 5. CatG deﬁciency raises plasma LDL but not HDL levels in LDL receptor deﬁcient mice. Plasma total cholesterol, triglyceride, LDL, and HDL levels (A), and plasma albumin and ALT
(alanine aminotransferase) levels (B) from Ldlr–/–Ctsg–/–mice and Ldlr–/–Ctsg+/+mice fed aWestern diet for 3 months and 6 months. Data aremean± SE. Number ofmice per experimen-
tal group is indicated in each bar.
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Brief incubation of LDL with CatG signiﬁcantly reduced the quantity of
native LDL (Peak 2, Fig. 6A). Since a fraction of LDL eluted in the void vol-
ume of the column (Peak 1), CatGmust have induced aggregation of the
protease-treated LDL [37]. Of note, a third peak (Peak 3) appeared after
CatG incubation— thematerial in this peak representing apoB-100 deg-
radation products and eluted CatG. In contrast, incubation of HDL3 with
CatG did not signiﬁcantly reduce the quantity of native HDL3 (Peak 1),
while the quantity of HDL3-derived peptides increased slightly (Peak
2, Fig. 6B). Ultracentrifugally isolated native HDL3 fraction containedTable 1
Clinical characteristics and plasma cathepsin G levels in patients with or without coronary hea
Variables Non-CHD
(n = 61)
SAP
(n =
Age (years) 45 (22, 74) 57 (3
Sex (female/male) 22/39 21/2
Type 2 diabetes mellitus (%) – 8.89
Hypertension (%) – 62.22
Total cholesterol (mmol/L) 4.22
(5.59, 2.74)
4.73⁎
(6.40
Triglyceride (mmol/L) 1.44
(2.18, 0.50)
1.74⁎
(4.66
LDL (mmol/L) 2.47
(3.64, 1.08)
2.81⁎
(4.81
HDL (mmol/L) 1.25
(2.07, 0.20)
1.30
(2.34
Cathepsin G (U/mL) 440.70
(40.00, 1874.70)
241.9
(10.4
AMI, acute myocardial infarction; HDL, high-density lipoprotein; LDL, low-density lipoprotein;
⁎ Values are expressed as median (minimum, maximum) or a percentage.
⁎⁎ P b 0.05 compared with the non-CHD group.
⁎⁎⁎ P b 0.01 compared with the non-CHD group.lower molecular weight material (Peak 2), which we have shown to
contain lipid-free and lipid-poor apoA-I detached from the HDL3 parti-
cles [38]. Moreover, a portion of the increase in Peak 2 can be explained
by the presence of eluted CatG. Taken together, while CatG degrades
apoB-100 and generates fragments, this enzyme does not alter HDL3
under the conditions used. This ﬁnding established a previously unrec-
ognized role of CatG in proteolysis of LDL, but notHDL, and explained in-
creased LDL cholesterol but not HDL cholesterol in Ldlr–/–Ctsg–/– mice
and negative association between plasma CatG and LDL cholesterol
but not HDL in patients with atherosclerotic coronary artery disease.rt disease (CHD)⁎.
45)
UAP
(n = 67)
AMI
(n = 59)
6, 78)⁎⁎⁎ 60 (25, 69)⁎⁎⁎ 62 (29, 79)⁎⁎⁎
4 32/35 9/50⁎⁎⁎
13.43 13.59
71.64 50.85
⁎
, 2.56)
4.89⁎⁎⁎
(8.46, 2.91)
4.64⁎⁎
(7.55, 3.03)
⁎⁎
, 0.56)
1.57
(4.29, 0.37)
2.03⁎⁎⁎
(7.90, 0.28)
⁎
, 1.82)
3.02⁎⁎⁎
(5.43, 1.72)
2.77⁎⁎
(5.45, 1.59)
, 0.68)
1.18
(2.52, 0.61)
1.03⁎⁎⁎
(2.31, 0.35)
0⁎⁎⁎
5, 1617.70)
330.00⁎⁎⁎
(74.05, 2468.00)
284.90⁎⁎⁎
(28.60, 1350.45)
SAP, stable angina pectoris; UAP, unstable angina pectoris.
Table 2
Correlation analysis of plasma cathepsin G with plasma lipid levels among all 232 patients.
Before adjustmenta After adjustmentb
Lipid Correlation coefﬁcient P value Correlation coefﬁcient P value
Total cholesterol (mmol/L) −0.535 1.886E−15 −0.504 1.369E−13
Triglyceride (mmol/L) −0.096 0.186 −0.052 0.475
Low−density lipoprotein (mmol/L) −0.559 4.997E−17 −0.502 1.911E−13
High-density lipoprotein (mmol/L) −0.009 0.901 −0.044 0.552
a Pearson's correlation analysis was performed before adjusting for lipid lowering (statin) treatment.
b Partial correlation test was performed with statin treatment as the controlling variable.
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As an elastase [16,17], CatG may promote arterial wall elastinolysis
and exacerbate atherosclerosis. An enzyme capable of producing Ang-II
[2,4,6], CatG may also enhance blood pressures and increase the risk of
CHD. This study used CatG-deﬁcient Ldlr–/–Ctsg–/– mice and established
a role of CatG in elastin fragmentation at early stage of atherogenesis.
Yet, when these mice consumed a Western diet for 6 months, absence
of CatG actually enlarged atherosclerotic lesion areas in the aortic arch
by nearly 2-fold (Fig. 3B) and increased plasma levels of total cholesterol
and LDL cholesterol, but not HDL cholesterol or triglyceride levels
(Fig. 5A), although CatG-deﬁciency still reduced diastolic blood pressure
and plasma Ang-II and ACE levels in these mice. The mechanistic studies
presented here disclose a heretofore unrecognized role for CatG in the
regulation of plasma total and LDL cholesterol levels directly byFig. 6. CatG processes plasma LDL but not HDL. Gelﬁltration chromatography of puriﬁed humanpl
CatG. Independent incubations were performed and each sample was analyzed once or twice, re
(HDL3) were calculated and presented as mean ± SD. Representative chromatograms of LDL and
U test.degrading apoB on LDL (while not affecting HDL), although our study
did not prove a role of CatG activity in Ang-II production in systolic or di-
astolic blood pressure changes during atherogenesis. A recent study
using Apoe–/–Ctsg+/+ and CatG-haploinsufﬁcient Apoe–/–Ctsg+/– mice
suggested an insigniﬁcant contribution of CatG in atherosclerosis in
these animals that accumulate primarily beta-VLDL rather than LDL
[21]. CatG may behave differently depending on the type of hyperlipid-
emia, as does the cysteine protease cathepsin S (CatS) which we dem-
onstrated signiﬁcantly reduces atherosclerosis in CatS-deﬁcient Ldlr–/–
Ctss–/–mice [23], but not in Apoe–/–Ctss–/–mice (unpublished data) com-
pared with corresponding CatS-sufﬁcient control mice.
Coronary angiographic studies often dichotomize those with b50%
coronary stenosis as “insigniﬁcant” CHD. Yet, some 40–50% of acute cor-
onary syndromes occur at sites with b50% luminal narrowing [39–41]
and increased stenosis correlates with reduced risk of coronary ruptureasma LDL (A) andHDL3 (B) before and after incubation for 18 hwith andwithout 2 mU/ml of
sulting in 4–6 chromatograms per sample. The areas of peaks 1–3 (LDL) and peaks 1 and 2
HDL3 are shown on the left. P b 0.05 is considered statistically signiﬁcant. Mann–Whitney
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atherosclerotic lesion ruptures [43,44]. CatG appears to contribute to
elastin fragmentation at the early stage (3 months) of atherogenesis
[16,17]. At this time point CatG deﬁciency in Ldlr–/–Ctsg–/–mice showed
signiﬁcantly reduced aortic arch elastin fragmentation, compared to
that in CatG-sufﬁcient Ldlr–/–Ctsg+/+ mice (Fig. 4D). In contrast, at a
later stage in atherogenesis (6 months), arterial wall elastin fragmenta-
tion increased over time in Ldlr–/–Ctsg–/–mice, but showed no signiﬁcant
difference between Ldlr–/–Ctsg–/– and Ldlr–/–Ctsg+/+ mice, suggesting
that elastin fragmentation by other elastinolytic proteases such as
cysteinyl cathepsins and MMPs becomes dominant in more advanced
atherosclerotic lesions [45,46]. Therefore, CatG elastinolytic activity in
non-ﬂow-limiting lesionsmay contribute to their propensity to rupture
in humans, a hypothesis that merits detailed investigation.
An LDL-lowering effect of CatG could protect animals and humans
from atherosclerosis, a hypothesis supported by several observations
from this study and prior studies. In mice, CatG deﬁciency accentuated
late-stage atherosclerosis, in association with increased plasma LDL
and total cholesterol levels (Fig. 5A). Human patients with CHD had
signiﬁcantly lower plasma CatG levels than did those without CHD
(Table 1), and plasma CatG levels correlated signiﬁcantly and negatively
with plasma LDL and total cholesterol levels before and after adjusting
for lipid-lowering medications (Table 2). In vitro, sub-physiological
concentration of human neutrophil CatG degraded puriﬁed human
LDL (Fig. 6A). This pathway of CatG in contributing to plasma LDL
level changesmay not operate in the presence of plasmaprotease inhib-
itors — such as α1-antichymotrypsin, an endogenous inhibitor of CatG
(and of neutrophil elastase and mast cell chymase) derived from mast
cells, neutrophils [47], hepatocytes, bronchial epithelial cells, and neu-
ronal cells [48,49]. But several lines of evidence support the hypothesis
that plasma α1-anti-chymotrypsin [50,51] has limited inhibitory activ-
ity on CatG-mediated LDL catabolism in vivo. First, a fraction of CatG
from human polymorphonuclear neutrophils [52], and probably other
inﬂammatory cells and vascular cells [53], may remain bound to cell-
surface negatively charged heparin proteoglycans. Such cell-surface-
bound CatG is catalytically active and remarkably resistant to naturally
occurring inhibitors from the plasma [29]. Second, other cell surface
heparin proteoglycan-bound proteases, such as chymase, have proven
most effective in LDL and HDL degradation when heparin-bound [54,
55]. After separation fromheparin proteoglycan, chymase becomes sus-
ceptible to physiological chymase inhibitors present in blood plasma
[56]. Third, ApoB-100 of LDL interacts nonspeciﬁcallywith the negative-
ly charged glycosaminoglycan chains of proteoglycan in the aortic inti-
ma at sites of cholesterol accumulation [57,58], and probably on the
surface of CatG-positive cells in the circulation. This protection from en-
dogenous inhibitors may facilitate ApoB proteolysis by proteoglycan-
bound CatG. In addition to inﬂammatory cells, vascular cell CatG may
alsomediate LDL catabolism in a similar manner. Subendothelial reten-
tion of LDL by binding to intimal proteoglycan occurs during atherogen-
esis [53], and ECs from human atherosclerotic lesions contain CatG
(Fig. 1B). Signiﬁcantly lower systemic CatG in CHD patients compared
with non-CHD patients (Table 1) may contribute directly to enhanced
plasma LDL levels (Fig. 5A, Table 1), thereby exacerbating atherosclerot-
ic lesion progression, as observed in the Ctsg–/– mice (Fig. 3B).
Although CatG-mediated extracellular elastin degradation may con-
tribute to atherogenesis, increased levels of the CatG inhibitor α1-anti-
chymotrypsin in human and experimental atherosclerotic lesions [59]
may limit secreted CatG's contribution to elastin degradation in patients
and animals with advanced atherosclerosis. In contrast, proteolysis of
LDL by cell surface-associated CatG in various compartments protects
the enzyme from α1-anti-chymotrypsin.
5. Conclusion
The results of this study reveal several novel cellular sources of CatG
expression in addition to mast cells and neutrophils in atheroscleroticlesions, notably SMCs, ECs, macrophages, and T cells. The results also
disclose novel roles of CatG in elastin degradation and cholesterol me-
tabolism, providing mechanistic insight into the diverse and previously
unknown functions of this serine proteinase in atherosclerosis.
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